The EpiPen Problem: Analyzing Unethical Drug Price Increases and the Need for Greater Government Regulation

In recent years, some pharmaceutical companies have started increasing the price of their existing drugs to exorbitant levels. Often, these drugs are medically necessary for patients, who are left to take on the high costs of the medicine. One recent example is Mylan, who raised the price of the EpiPen by four hundred percent, solely for the profit of its own company and to the detriment of consumers who rely on the EpiPen. Similar patterns of drug price increases have occurred in the past and will likely happen again in the future. This Comment will seek to identify the common elements of this pattern of increasing drug prices by looking at the behavior of corporations like Mylan and the way they operate, and it will assess current approaches to resolving this issue by looking at the roles of Congress, the Food and Drug Administration (FDA), and the Federal Trade Commission (FTC). The area of concern—apart from the way patients suffer from drug price increases—is that even after these companies are subjected to Congressional hearings to address their increasing drug prices, receive hefty fines from the FTC, experience bad press, and draw criticism about the issue of increasing drug prices, little change is made to resolve this problem. At the same time, industrialized nations around the world do not face the issue of increasing drug prices to the extent seen in the United States. Three countries—Canada, Switzerland, and France—have protected their citizens by structuring their healthcare system in a way that gives pharmaceutical companies little room to raise drug prices to high levels. These countries utilize approaches such as implementing a price ceiling, negotiating with pharmaceutical companies by looking at a drug’s therapeutic value, and setting a reassessment standard to periodically check on pharmaceutical companies. To this end, this Comment will look at these approaches in more detail and will analyze how they can be applied to the United States’ own healthcare system in a way that would prevent pharmaceutical companies from raising the prices of their drugs to unethical levels and, ultimately, lower the cost of prescription drugs

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.